Malonato platinum compounds

Claim 5

A composition suitable for parenteral administration to an animal affected with a malignant tumor sensitive to a planar dsp 2 platinum(II) coordination compound or an octahedral d 2 sp 3 platinum(IV) coordination compound comprising a pharmaceutically acceptable carrier and a platinum coordination compound of the formula: [Pt(II)A.sub.x (OOC).sub.2 --CRR.sub.1 ] or cis or trans [Pt(IV)A.sub.x ((OOC).sub.2 --CRR.sub.1).sub.y L.sub.z ] wherein: x=1 or 2; y=1 or 2; z=0, 1 or 2, provided that when y=2, z=0, and when y=1, z is greater than 0; R and R 1 are selected from the group consisting of H, lower alkyl, aryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, OH and combine with the carbon atom to form a cycloalkyl or cycloalkenyl group; when x=1, A is HR 2 N--CHR 3 --CHR 4 --NR 5 H and when x=2, A is H 2 NR 6 or an amino acid; wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of H, CH 3 , C 2 H 5 , hydroxy and lower alkoxy, provided that R 2 and R 5 may also be aryl or aralkyl and each R 6 is the same or different and is selected from the group consisting of H, lower alkyl, aryl, aralkyl, hydroxy lower alkyl, hydroxyl- and alkoxyl-amines and alkoxyl alkyl amines; when z=1, L is a bidentate anionic ligand, and when z=2, L is a monodentate anionic ligand, said compound being present in an amount sufficient to cause regression of said tumor.

Claim 6

A composition suitable for parenteral administration to an animal affected with a malignant tumor sensitive to a planar dsp 2 platinum(II) coordination compound or an octahedral d 2 sp 3 platinum(IV) coordination compound comprising a pharmaceutically acceptable carrier and a platinum coordination compound of the formula: [Pt(II)A.sub.x (OOC).sub.2 --CRR.sub.1 ] or cis or trans [Pt(IV)A.sub.x ((OOC).sub.2 --CRR.sub.1).sub.y L.sub.z ] wherein: x=1 or 2; y=1 or 2; z=0, 1 or 2, provided that when y=2, z=0, and when y=1, z is greater than 0; R and R 1 are selected from the group consisting of H, lower alkyl, aryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, OH and combine with the carbon atom to form a cycloalkyl or cycloalkenyl group; when x=1, A is HR 2 N--CHR 3 --CHR 4 --NR 5 H and when x=2, A is H 2 NR 6 or an amino acid; wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of H, CH 3 , C 2 H 5 , hydroxy and lower alkoxy, provided that R 2 and R 5 may also be aryl or aralkyl and each R 6 is the same or different and is selected from the group consisting of H, lower alkyl, aryl, aralkyl, hydroxy lower alkyl, hydroxyl- and alkoxyl-amines and alkoxyl alkyl amines; when z=1, L is a bidentate anionic ligand, and when z=2, L is a monodentate anionic ligand, said compound being present in an amount sufficient to cause regression of said tumor.

Claim 7

A composition suitable for oral administration to an animal affected with a malignant tumor sensitive to a planar dsp 2 platinum(II) coordination compound or an octahedral d 2 sp 3 platinum(IV) coordination compound comprising a pharmaceutically acceptable carrier and a platinum coordination compound of the formula: [Pt(II)A.sub.x (OOC).sub.2 --CRR.sub.1 ] or cis or trans [Pt(IV)A.sub.x ((OOC).sub.2 --CRR.sub.1).sub.y L.sub.z ] wherein: x=1 or 2; y=1 or 2; z=0, 1 or 2, provided that when y=2, z=0, and when y=1, z is greater than 0; R and R 1 are selected from the group consisting of H, lower alkyl, aryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, OH and combine with the carbon atom to form a cycloalkyl or cycloalkenyl group; when x=1, A is HR 2 N--CHR 3 --CHR 4 --NR 5 H and when x=2, A is H 2 NR 6 or an amino acid; wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of H, CH 3 , C 2 H 5 , hydroxy and lower alkoxy, provided that R 2 and R 5 may also be aryl or aralkyl and each R 6 is the same or different and is selected from the group consisting of H, lower alkyl, aryl, aralkyl, hydroxy lower alkyl, hydroxyl- and alkoxyl-amines and alkoxyl alkyl amines; when z=1, L is a bidentate anionic ligand, and when z=2, L is a monodentate anionic ligand, said compound being present in an amount sufficient to cause regression of said tumor.

Claim 8

A composition suitable for oral administration to an animal affected with a malignant tumor sensitive to a planar dsp 2 platinum(II) coordination compound or an octahedral d 2 sp 3 platinum(IV) coordination compound comprising a pharmaceutically acceptable carrier and a platinum coordination compound of the formula: [Pt(II)A.sub.x (OOC).sub.2 --CRR.sub.1 ] or cis or trans [Pt(IV)A.sub.x ((OOC).sub.2 --CRR.sub.1).sub.y L.sub.z ] wherein: x=1 or 2; y=1 or 2; z=0, 1 or 2, provided that when y=2, z=0, and when y=1, z is greater than 0; R and R 1 are selected from the group consisting of H, lower alkyl, aryl, aralkyl, alkenyl, cycloalkyl, cycloalkenyl, alkoxy, OH and combine with the carbon atom to form a cycloalkyl or cycloalkenyl group; when x=1, A is HR 2 N--CHR 3 --CHR 4 --NR 5 H and when x=2, A is H 2 NR 6 or an amino acid; wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of H, CH 3 , C 2 H 5 , hydroxy and lower alkoxy, provided that R 2 and R 5 may also be aryl or aralkyl and each R 6 is the same or different and is selected from the group consisting of H, lower alkyl, aryl, aralkyl, hydroxy lower alkyl, hydroxyl- and alkoxyl-amines and alkoxyl alkyl amines; when z=1, L is a bidentate anionic ligand, and when z=2, L is a monodentate anionic ligand, said compound being present in an amount sufficient to cause regression of said tumor.